B
BIIB
Biogen Inc
216.78
+2.43+1.13%After Hours: 216.78 0.00 0.00%19:30 08/21 EDT
OPEN/PREV CLOSE217.76/214.35
TODAY RANGE215.00-219.12
VOL722.35K
MARKET CAP32.03B
52 WEEK RANGE131.52-222.15
AVG VOL (3M)1.17M
% TURNOVER0.49%
TURNOVER--
P/E (TTM)38.39
% RANGE1.92%
EPS(TTM)5.65
P/E(FORWARD)38.52
P/B1.699
BVPS127.61
DIVIDEND--
P/S3.215
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP31.89B
SHARES OUTSTANDING147.75M
NEXT EARNINGS10/28-11/02
FREE FLOAT147.10M
LOT SIZE1
EX-DATE02/02/2017
News
Press Releases
Financial Reports
Profile
Simply Wall St·22h ago
How Investors Are Reacting To Biogen (BIIB) Raising EPS Guidance On Late-Stage Drug Trial Milestones
Seeking Alpha·1d ago
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
Simply Wall St·2d ago
Biogen (BIIB) And The Alzheimer’s Narrative As Valuation Stays In Focus
Seeking Alpha·3d ago
Trump nominates White House adviser Overton as next FDA commissioner
Seeking Alpha·4d ago
Trump expected to nominate White House aide Heidi Overton as FDA commissioner
TipRanks·6d ago
Wolfe upgrades Biogen to Outperform on late-stage pipeline
Simply Wall St·6d ago
Biogen (BIIB) Stock Stays Cheap on Cash Flow but Pricey on Earnings
Seeking Alpha·08/14 12:31
Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s
Dow Jones·08/13 17:26
Biogen Price Target Announced at $300.00/Share by Wolfe Research
Dow Jones·08/13 17:26
Biogen Raised to Outperform From Peer Perform by Wolfe Research
Benzinga·08/13 17:18
Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target